| Gene ID | 5243 |
| Symbol | ABCB1 |
| Synonymous | ABC20|CD243|CLCS|GP170|MDR1|P-GP|PGY1 |
| Full name | ATP-binding cassette, sub-family B (MDR/TAP), member 1 |
| Gene description | P-glycoprotein 1|colchicin sensitivity|doxorubicin resistance|multidrug resistance protein 1 |
| Cytoband | 7q21.12 |
| Gene type | protein-coding |
| Synonymous | MIM:171050; HGNC:HGNC:40; Ensembl:ENSG00000085563; HPRD:01370; Vega:OTTHUMG00000023393 |
Pathways and Diseases | Detail |
|---|---|
Pathway | multi-drug resistance factors;PID BioCarta;100103 |
Pathway | ABC transporters;KEGG PATHWAY;hsa02010 |
Pathway | HIF-1-alpha transcription factor network;PID Curated;200172 |
Pathway | hypoxia and p53 in the cardiovascular system;PID BioCarta;100084 |
Disease | tacrolimus dose requirements;GAD |
Disease | heart transplant;GAD |
Disease | inflammatory bowel disease;GAD |
Disease | indinavir pharmacokinetics;GAD |
Disease | steroid weaning;GAD |
Disease | breast cancer;GAD |
Disease | Alzheimer's disease;GAD |
Disease | altered efflux of the P-glycoprotein substrate rhodamine;GAD |
Disease | Crohn's disease;GAD |
Disease | paclitaxel toxicity;GAD |
Disease | Inflammatory bowel disease 13, susceptibility to;OMIM |
Disease | fluvoxamine pharmacokinetics;GAD |
Disease | tacrolimus pharmacokinetics;GAD |
Disease | aldosterone blood pressure, arterial kidney function left ventricular function;GAD |
Disease | cyclosporine nephrotoxicity;GAD |
Disease | lung transplant complications;GAD |
Disease | cyclosporine resistance;GAD |
Disease | nasopharyngeal cancer;GAD |
Disease | Crohn's disease ulcerative colitis;GAD |
Disease | hypertension;GAD |
Disease | docetaxel pharmacokinetics;GAD |
Disease | fentanyl effects;GAD |
Disease | HIV;GAD |
Disease | ebastine metabolism;GAD |
Disease | schizophrenia;GAD |
Disease | PHARMACOGENOMIC;GAD |
Disease | loperamide concentration;GAD |
Disease | METABOLIC;GAD |
Disease | amlodipine pharmacokinetics;GAD |
Disease | kidney dysfunction;GAD |
Disease | prolactin;GAD |
Disease | tacrolimus pharmcokinetics;GAD |
Disease | irinotecan pharmacokinetics irinotecan toxicity lung cancer;GAD |
Disease | PSYCH;GAD |
Disease | epilepsy phentoin levels;GAD |
Disease | HIV Infections;GAD |
Disease | CARDIOVASCULAR;GAD |
Disease | digoxin, serum concentration;GAD |
Disease | CANCER;GAD |
Disease | epilpsy;GAD |
Disease | simvastatin;GAD |
Disease | major depression;GAD |
Disease | epilepsy;GAD |
Disease | cyclosporine pharmacokinetics;GAD |
Disease | renal cancer;GAD |
Disease | leukemia, acute myeloid;GAD |
Disease | NEUROLOGICAL;GAD |
Disease | IMMUNE;GAD |
Disease | ulcerative colitis;GAD |
Disease | cholesterol, LDL;GAD |
Disease | cholesterol;GAD |
Disease | antiemetic response;GAD |
Disease | plasma cell myeloma;GAD |
Disease | leukemia;GAD |
Disease | liver cancer;GAD |
Disease | renal function;GAD |
Disease | methotrexate toxicity;GAD |
Disease | liver transplant;GAD |
Disease | Hypotension;GAD |
Disease | INFECTION;GAD |
Disease | Colchicine resistance;OMIM |
Disease | lung cancer;GAD |
Disease | ovarian cancer;GAD |
Disease | pravastatin kinetics;GAD |
Disease | RENAL;GAD |
Sequence Information | |
|---|---|
Nucleotide Sequence | >5243 : length: 4718 AAACACTTGTATTACCATTTTAAAGGCTATCATTACTCTTTACCTGTGAAGAGTAGAACATGAAGAAATCTACTTTATTCAGATATTCTCCAGATTCCTAAAGATTAGAGATCATTTCTC ATTCTCCTAGGAGTACTCACTTCAGGAAGCAACCAGATAAAAGAGAGGTGCAACGGAAGCCAGAACATTCCTCCTGGAAATTCAACCTGTTTCGCAGTTTCTCGAGGAATCAGCATTCAG TCAATCCGGGCCGGGAGCAGTCATCTGTGGTGAGGCTGATTGGCTGGGCAGGAACAGCGCCGGGGCGTGGGCTGAGCACAGCCGCTTCGCTCTCTTTGCCACAGGAAGCCTGAGCTCATT CGAGTAGCGGCTCTTCCAAGCTCAAAGAAGCAGAGGCCGCTGTTCGTTTCCTTTAGGTCTTTCCACTAAAGTCGGAGTATCTTCTTCCAAAATTTCACGTCTTGGTGGCCGTTCCAAGGA GCGCGAGGTCGGAATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAACAATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGT ATTTTCAATGTTTCGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATCCATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGAC AGATATCTTTGCAAATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGATACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTA TTATTACAGTGGAATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCTGGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAAT GCGACAGGAGATAGGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCCAAGATTAATGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTC AATGGCAACATTTTTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCCATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACT ATCTTCATTTACTGATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCAATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAG GTACAACAAAAATTTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGTGCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTA TGGGACCACCTTGGTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATTGGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGC AAATGCAAGAGGAGCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAGAGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAA TGTTCACTTCAGTTACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTGAAGGTGCAGAGTGGGCAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAAC AGTCCAGCTGATGCAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACCATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGA ACCTGTATTGTTTGCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATTGAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACT GCCTCATAAATTTGACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCCATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGA GGCCACGTCAGCCTTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGGACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGA CGTCATCGCTGGTTTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGCATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGA ATTAGAAAATGCAGCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCCAGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACA AGCCCAAGACAGAAAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATTATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATT TTGTGCCATTATAAATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACAAGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTC ACTATTGTTTCTAGCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCTGGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCAT GCTCAGACAGGATGTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAATGATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAAT TACCCAGAATATAGCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTACTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAAT GAAAATGTTGTCTGGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTTCTGGGAAGATCGCTACTGAAGCAATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTT TGAACATATGTATGCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATTACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATG TTTCCGGTTTGGAGCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCTGTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCC TGACTATGCCAAAGCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGCTACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCAC ATTTGGTGAAGTTGTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTGAAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAA GAGCACAGTGGTCCAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAAATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGT GTCCCAGGAGCCCATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTGTCACAGGAAGAGATTGTGAGGGCAGCAAAGGAGGCCAACATACATGC CTTCATCGAGTCACTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAGAAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATAT TTTGCTTTTGGATGAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAAGCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCAC CATCCAGAATGCAGACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTGCTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGG AACAAAGCGCCAGTGAACTCTGACTGTATGAGATGTTAAATACTTTTTAATATTTGTTTAGATATGACATTTATTCAAAGTTAAAAGCAAACACTTACAGAATTATGAAGAGGTATCTGT TTAACATTTCCTCAGTCAAGTTCAGAGTCTTCAGAGACTTCGTAATTAAAGGAACAGAGTGAGAGACATCATCAAGTGGAGAGAAATCATAGTTTAAACTGCATTATAAATTTTATAACA GAATTAAAGTAGATTTTAAAAGATAAAATGTGTAATTTTGTTTATATTTTCCCATTTGGACTGTAACTGACTGCCTTGCTAAAAGATTATAGAAGTAGCAAAAAGTATTGAAATGTTTGC ATAAAGTGTCTATAATAAAACTAAACTTTCATGTGAAA |
Protein Sequence | >5243 : length: 1280 MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAIIHGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVSKINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIGAAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIAIARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRSSLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKAGEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEAIENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDSYSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVVSQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQLLAQKGIYFSMVSVQAGTKRQ |